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only, 50 and 100 mg, 100 mg only) Rates of serious infections,
malignancies, and death were 13.9%, 4.6%, and 2.1%, respectively.
12.3% of pts had 1 injection-site reaction. Of 388 pts with available
samples, 31 (8.0%) tested positive for antibodies to GLM.
Conclusion: GLM efficacy was maintained through 5 years among pts
with refractory RA who continued treatment. The long-term safety of
GLM is consistent with other anti-TNFa agents.
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Background: At Year 1 of the AMPLE (Abatacept Versus Adalimumab
Comparison in Biologic-Naive RA Subjects with Background MTX)
study, s.c. abatacept (ABA) and adalimumab (ADA) demonstrated
comparable efficacy, including radiographic outcomes, with similar
safety. Here we report 2-year results.
Methods: AMPLE is a Phase IIIb, randomized, investigator-blinded
study. Biologic-naı¨ve patients with active RA and an inadequate
response to MTX were randomized to 125 mg ABA weekly or 40 mg
ADA bi-weekly, with background MTX. Clinical efficacy endpoints
were captured through Day 729, including radiographs assessed using
the van der Heijde modified Total Sharp score (mTSS). All efficacy
analyses were done using the intent-to-treat population, with non-
responder imputation where appropriate. All radiographs were read
through Day 729, including re-reading Year 1 images, by readers
blinded to treatment allocation and sequence.
Results: Baseline characteristics of the 646 patients were comparable
between treatments. 79.2% (252/318) ABA patients and 74.7%
(245/328) ADA patients completed Day 729. At Year 1, 64.8% ABA
and 63.4% ADA patients were ACR20 responders. Consistent with
Year 1, clinical efficacy measures and inhibition of radiographic
progression were comparable between groups at Year 2 (Table 1).
There were similar rates of AEs, SAEs (13.8% vs 16.5%) and
malignancies (2.2% vs 2.1%). More autoimmune AEs occurred in the
ABA arm (3.8% vs 1.8%); none were SAEs. Fewer infections (3.8% vs
5.8%) and opportunistic infections (3 vs 5 patients) occurred with ABA,
including two cases of tuberculosis in the ADA arm that led to
discontinuation (DC). There were fewer DCs due to AEs (3.8% vs
9.5%), SAEs (1.6% vs 4.9%) and serious infections (0/12 vs 9/19
patients) in the ABA arm. Injection-site reactions (ISRs) occurred less
frequently in the ABA arm (4.1% vs 10.4%).
Conclusion: Through 2 years of treatment in this first active
comparator study between biologic agents in RA patients with an
inadequate response to MTX, s.c. abatacept and adalimumab were
equally efficacious in clinical, functional and radiographic outcomes.
Overall, the frequency of AEs was similar in both groups but there were
fewer discontinuations due to AEs, SAEs, serious infections, and fewer
local ISRs in abatacept-treated patients. This study was supported by
Bristol-Myers Squibb.
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Background: There is a need to compare ACR responses of novel
DMARDs, as monotherapy or in combination with MTX, in RA patients
with an inadequate response to conventional DMARDs (DMARD-IR
patients).
Methods: A systematic literature review identified 30 randomized
clinical trials (RCTs) that evaluated abatacept (i.v. and s.c.), anakinra,
adalimumab, certolizumab pegol, etanercept, golimumab, infliximab,
tofacitinib, and tocilizumab (TCZ) (i.v. and s.c.). Reported treatment
effects in terms of ACR responses at 24 weeks were synthesized by
means of Bayesian network meta-analyses to allow comparisons of
the different treatments as monotherapy and combination therapy.
Based on previous reviews an assumption was made that the effects
of anti-tumour necrosis factor (aTNF) therapy were exchangeable.
Given this, and the limited data identified for these therapies in
monotherapy, aTNF data were pooled.
Results: aTNFsþMTX, tofacitinibþMTX, abatacept i.v./s.c.þMTX,
and TCZ i.v./s.c.þMTX demonstrated comparable ACR responses
while anakinraþMTX was less efficacious. Among biologic mono-
therapies, greater ACR20/50/70 responses were observed with TCZ
than with aTNFs and tofacitinib. When comparing biologicsþMTX with
biologic monotherapies, ACR20, ACR50, and ACR70 responses with
TCZþMTX were similar to TCZ as monotherapy (OR 1.04, 95% CI
0.39, 2.80; OR¼1.28, 95% CI 0.46, 3.51; OR 0.97, 95% CI 0.38, 2.49,
respectively), whereas with aTNFþMTX greater ACR20/50/70
responses were observed than with aTNF monotherapy (OR 2.22;
95% CI 0.46, 10.83, probability better 84%; OR 3.12, 95% CI 0.60,
16.32, probability better 92%; OR 1.39, 95% CI 0.26, 6.78, probability
better 68%, respectively). For tofacitinib, sensitivity analyses showed
conflicting results for the indirect comparison of tofacitinibþMTX vs
tofacitinib.
Conclusion: Results of this meta-analysis suggest that most available
novel DMARDs, in combination with MTX, have similar levels of
efficacy in DMARD-IR patients. As monotherapy, TCZ is likely to have
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a greater response than aTNFs and tofacitinib. TCZ monotherapy also
shows comparable efficacy compared with TCZþMTX, whereas
aTNFs in combination with MTX showed greater ACR responses
compared with aTNF monotherapy at 24 weeks.
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Background: EULAR recommendations advocate MTX as first line
therapy. For patients (pts) who fail to attain remission or low disease
activity (LDA) after 6 months of MTX treatment, TNF inhibitors should
be added to the therapeutic regimen in pts with high risk of bad
outcome. This post hoc analysis examined outcomes following open
label (OL)-adalimumab (ADA)þMTX in RA pts who did not achieve a
stable LDA target at 22 and 26 weeks either from ADAþMTX or MTX
monotherapy. Consequences of optimizing or not optimizing therapy
were assessed.
Methods: OPTIMA was a 78 week, randomized, double-blind, double-
treatment period study designed to compare safety and efficacy of
ADAþMTX with placebo (PBO)þMTX in early RA pts. Following
ADAþMTX or PBOþMTX treatment for 26 weeks (Period-1), non-
responders (NR) were defined as pts failing to achieve a stable LDA
target of DAS28(CRP) <3.2 at week 22 and week 26 and given OL-
ADAþMTX for an additional 52 weeks (Period-2) (OL-ADA Carry On
and Rescue-ADA arms, respectively). Period-2 responders were
defined as those achieving LDA at week 52 following OL-ADAþMTX
therapy. Logistic regression analysis was conducted with baseline and
week 26 disease characteristics as variables.
Results: Compared with responders, Period-1 NR began the study
with higher overall disease activity. Among these, 78/259 (30%)
OL-ADA Carry On and 157/348 (45%) Rescue-ADA pts achieved
DAS28 (CRP) <3.2 following 26 weeks of OL-ADAþMTX therapy; 33/
259 (13%) and 49/348 (14%) OL-ADA Carry On and Rescue-ADA pts,
respectively, had DAS28 (CRP) 3.2 at week 52 and achieved DAS28
(CRP) <3.2 at week 78. Mean values of responders’ clinical,
radiographic, and functional outcomes were much lower than those
of NR and were similar to those seen for pts who achieved the
treatment target within Period-1. This indicates that starting with MTX
followed by ADA in insufficient responders to MTX is an appropriate
strategy; a small subset of pts responds more slowly to MTX/ADA
combination from start (Table 1). ACR20/50/70 scores for the Rescue-
ADA arm from week 26 to week 78 were sizeable (51%, 34%, and
19%, respectively). OL-ADA Carry On arm achieved ACR20/50/70
from week 26 baseline in 27%, 15%, and 8% of pts, respectively, at
week 78. Age, patient and physician’s global assessment of disease,
and tender/swollen joint counts were all predictors of achieving DAS28
(CRP) <3.2 at week 78.
Conclusion: When advanced to OL-ADAþMTX therapy, pts initially
not achieving stable LDA target at week 26 following MTX mono-
therapy demonstrated improvements in clinical and functional out-
comes at week 52 and week 78, structural progression was minimal.
Some improvement was also seen among pts who did not yet attain
stable LDA at week 26 on ADAþMTX but continued this treatment;
however, it remains unknown whether pts who were not in LDA at
week 78 might have benefited from earlier treatment adjustment in an
attempt to further improve outcomes.
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Background: Adalimumab is a fully human monoclonal antibody
known to be effective in the treatment of RA. Previous studies have
reported that after an initial response, some RA patients may lose
response to adalimumab over time. One explanation is immunogeni-
city of adalimumab leading to the development of antibodies against
the drug. Radioimmunoassay (RIA) is a sensitive method to detect
anti-drug antibodies (ADAb). The aim was to use RIA to evaluate the
occurrence of antibodies against adalimumab in a cohort of RA
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